Clinical trials: Untreated B-CLL
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
This study is testing the effectiveness of the study drug combination of acalabrutinib, umbralisib, and ublituximab in participants with Chronic Lymphocytic leukemia (CLL).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT04624633
- Testing
- Acalabrutinib, Umbralisib, Ublituximab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jennifer R. Brown, MD, PhD
Chronic Lymphocytic Leukemia
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL).
- Trial name
- ASSURE (NCT04008706)
- Testing
- Acalabrutinib
- Where
- 108 sites in United States, Australia and 15 more
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL).
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- NCT01361711
- Testing
- alemtuzumab, ofatumumab, biopsy
- Where
- 2 sites in United States, Sweden
- Volunteers
- 53 people
- Sponsor
- Northwestern University
Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
This randomized phase I/II trial studies the side effects and the best dose of temsirolimus when given together with bortezomib, rituximab, and dexamethasone and to see how well they work compared to bortezomib, rituximab, and…
- Conditions
- Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma
- Trial name
- NCT01381692
- Testing
- Bortezomib, Dexamethasone, Laboratory Biomarker Analysis
- Where
- 11 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia
- Trial name
- NCT01109264
- Testing
- Bendamustine hydrochloride injection, Chlorambucil
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Leukemia
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
The goal of this clinical research study is to learn if urelumab given in combination with rituximab can help to control CLL or SLL. The safety of the drug combination will also be studied.
- Trial name
- NCT02420938
- Testing
- Rituximab, Urelumab
- Sponsor
- M.D. Anderson Cancer Center
Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
This is a multicenter, open-label Phase 1 study of acalabrutinib, a selective and irreversible Bruton's tyrosine kinase inhibitor, in Japanese adult patients with advanced B-cell malignancies.
- Conditions
- Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL
- Trial name
- NCT03198650
- Testing
- Acalabrutinib, Obinutuzumab
- Where
- 13 sites in Japan
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Leukemia
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00858117
- Testing
- Alemtuzumab, Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
- Trial name
- SEQUOIA (NCT03336333)
- Testing
- Zanubrutinib, Bendamustine, Rituximab
- Where
- 158 sites in United States, Australia and 13 more
- Volunteers
- 590 people
- Sponsor
- BeiGene
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase I trial studies the side effects of vaccine therapy in preventing cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01588015
- Testing
- tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Chronic Lymphocytic Leukemia
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00769522
- Testing
- Rituximab, Bendamustine, Cyclophosphamide
- Where
- Germany
- Volunteers
- 564 people
- Sponsor
- German CLL Study Group
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia .
- Trial name
- NCT05336812
- Testing
- Acalabrutinib, Obinutuzumab, Venetoclax
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Leukemia
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.
- Trial name
- CLL-8 (NCT00281918)
- Testing
- Rituximab, Cyclophosphamide, Fludarabine Phosphate
- Where
- 162 sites in Australia, Austria and 9 more
- Volunteers
- 817 people
- Sponsor
- Hoffmann-La Roche
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
This phase I/II trial studies whether a new kind of blood stem cell (bone marrow) transplant, that may be less toxic, is able to treat underlying blood cancer. Stem cells are "seed cells" necessary to make blood cells.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome
- Trial name
- NCT00027820
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 106 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of decitabine and FR901228 in treating patients with relapsed or refractory leukemia, myelodysplastic syndromes or myeloproliferative disorders.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00114257
- Testing
- decitabine, romidepsin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic…
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- NCT01886872
- Testing
- Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 937 sites in United States, Canada
- Volunteers
- 547 people
- Sponsor
- National Cancer Institute (NCI)